NASDAQ:FHTX Foghorn Therapeutics Q3 2026 Earnings Results & Report $1.86 -0.18 (-8.58%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Foghorn Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of $0.80 versus the -$0.2356 consensus estimate, while revenue of $83.54 million topped the $7.10 million estimate by $76.45 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Foghorn Therapeutics EPS ResultsActual EPS$0.80Consensus EPS -$0.2356Beat/MissBeat by +$1.0356One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersFoghorn Therapeutics Revenue ResultsActual Revenue$83.54 millionExpected Revenue$7.10 millionBeat/MissBeat by +$76.45 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Foghorn Therapeutics Q3 2026 Earnings FAQ Did Foghorn Therapeutics beat earnings estimates for Q3 2026? Foghorn Therapeutics (NASDAQ:FHTX) reported earnings of $0.80 per share for Q3 2026, beating the consensus estimate of -$0.2356. The report was announced on Monday, November 9, 2026. What was Foghorn Therapeutics' revenue for Q3 2026? Foghorn Therapeutics reported revenue of $83.54 million for Q3 2026, against a consensus estimate of $7.10 million. Foghorn Therapeutics Earnings HeadlinesFoghorn Q3 Swings To Profit On Collaboration Revenue; Cash Runway Extends Into 2029November 9 at 3:32 PM | rttnews.comFoghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate UpdateNovember 9 at 7:22 AM | globenewswire.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNovember 5, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNovember 3, 2026 | globenewswire.comFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in NovemberNovember 3, 2026 | globenewswire.comSee More Foghorn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email. Email Address About Foghorn TherapeuticsFoghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company focused on developing medicines that target the chromatin regulatory system, which controls how DNA is packaged and how genes are expressed. The company’s research is directed primarily toward cancer therapies, particularly for tumors driven by abnormalities in chromatin-remodeling proteins. Foghorn uses its proprietary Gene Traffic Control platform to identify and develop small-molecule treatments designed to modulate chromatin-regulating complexes. Its pipeline has included FHD-609, a BRD9-targeting protein degrader, and FHD-286, an inhibitor intended to address vulnerabilities associated with the BRG1 and BRM chromatin-remodeling proteins. These programs have been evaluated in selected hematologic and solid-tumor indications. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn conducts drug discovery and clinical development activities for patients in the United States and other regions where its studies are authorized. The company has also pursued research collaborations with larger pharmaceutical companies to advance programs based on its chromatin biology platform. Adrian Gottschalk serves as Foghorn Therapeutics’ president and chief executive officer.View Foghorn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
